Trevi Therapeutics (TRVI) Announces Proposed $100M Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Nasdaq, S&P 500 futures rise ahead of key jobs report
- Oil rallies for the week as U.S.-Iran fighting resumes; diesel hits record high
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- Fed’s Waller open to September rate hold - if disinflation holds up
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
June 2, 2025 4:01 PM EDTNEW HAVEN, Conn., June 2, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the... More
